Hopstem's hNPC01 Earns FDA RMAT Designation for Chronic Stroke, Expands into Hemorrhagic Stroke and TBI
Key Insights
Hopstem Biotechnology (search)'s hNPC01, an iPSC (search)-derived forebrain neural progenitor cell therapy, received the first-ever FDA RMAT designation for chronic motor dysfunction due to basal ganglia ischemic stroke.
The FDA also cleared IND applications and granted Fast Track designations for hNPC01 in hemorrhagic stroke (search) and traumatic brain injury (search), expanding clinical development across three major brain injury indications.
Phase I data showed patients achieved a mean 16-point improvement on the Fugl-Meyer Motor Scale at 12 months, with over 92% achieving clinically meaningful motor recovery at 18 months.
Hopstem Biotechnology (search) has secured the first Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for its proprietary human forebrain neural progenitor cell injection, hNPC01, targeting persistent motor dysfunction due to basal ganglia ischemic stroke. This milestone establishes hNPC01 as the world's first forebrain neural progenitor cell therapy to receive FDA RMAT designation and marks the inaugural RMAT approval globally for any therapeutic targeting chronic motor impairment stemming from stroke and other neurological injuries.
The RMAT designation will grant Hopstem a dedicated comprehensive consultation meeting with the FDA to accelerate the formulation of streamlined clinical development and commercial manufacturing roadmaps, enabling the company to efficiently compile critical evidence for regulatory approval.
Expanding Across Three Major Brain Injury Indications
Building on this momentum, Hopstem announced on July 29, 2026, that the FDA cleared its Investigational New Drug (IND) application and granted Fast Track designations for hNPC01 in two additional indications: chronic motor dysfunction due to hemorrhagic stroke (search) (ICH) and traumatic brain injury (search) (TBI). These represent the world's first FDA-authorized clinical programs of an iPSC (search)-derived forebrain neural progenitor cell therapy for motor impairment after ICH and TBI.
"Receiving IND clearance and Fast Track Designations for both hemorrhagic stroke (search) and traumatic brain injury (search) represents a major regulatory milestone for hNPC01 and underscores the urgent clinical demand for regenerative treatments for chronic brain injury survivors," said Dr. Jing Fan, CEO of Hopstem Biotechnology (search). "We are encouraged by FDA's recognition of hNPC01's potential to address a devastating gap in patient care."
The Unmet Clinical Need
Globally, nearly 100 million individuals live with post-stroke sequelae, including over 7.8 million patients in the United States, with approximately 850,000 new stroke cases diagnosed each year. Due to the absence of effective neurorestorative therapies for chronic stroke — defined as one year or more post-onset — roughly 50% of survivors face permanent, lifelong disability.
For hemorrhagic stroke (search) specifically, around 3.4 million new cases occur globally each year, with 50%–60% of ICH survivors experiencing significant chronic motor deficits one year after onset, predominantly hemiparesis, spasticity, and gait dysfunction. In the U.S., roughly 70,000–95,000 new hemorrhagic strokes are recorded annually.
Worldwide, approximately 69 million people sustain a TBI each year. In the U.S., an estimated 2.8 million TBIs occur annually, with roughly 15%–20% classified as moderate-to-severe. Clinical cohorts demonstrate that nearly 30% of moderate-to-severe TBI survivors struggle with sustained walking impairment two years post-injury, and approximately 25% endure long-term upper and lower extremity motor control deficits.
No targeted curative treatments are currently available for a broad spectrum of forebrain injuries and degenerative disorders, including traumatic brain injury (search) and cerebral palsy.
Clinical Evidence Supporting hNPC01
Encouraging safety and efficacy findings from Hopstem's Phase I clinical studies of hNPC01 in patients with chronic motor dysfunction due to ischemic stroke have been reported. No product-related adverse events other than manageable immune responses were observed in participants for up to 2.5 years, and no treatment-related neurological deterioration has been reported.
Key clinical findings include a mean improvement of 16 points on the Fugl-Meyer Motor Scale (FMMS) at 12 months in the target subgroup, with nearly 80% achieving clinically significant improvement defined as a 10-point or greater gain. At 18 months, more than 92% of patients achieved clinically meaningful motor recovery, while 54% demonstrated at least a one-level improvement on the modified Rankin Scale (mRS). Two-year follow-up data indicate durable clinical benefit, with functional improvement maintained through a sustained efficacy plateau.
Mechanism and Preclinical Validation
Preclinical studies published in Nature Communications demonstrate that hNPC01 can differentiate into functional cerebral neurons in vivo, integrate into multi-region brain neural circuits, and repair endogenous neural networks. hNPC01 is an allogeneic human forebrain neural progenitor cell product differentiated from clinical-grade iPSCs using Hopstem's proprietary second-generation differentiation platform. Following intracranial delivery, cells mature into forebrain-type neurons and glia, supporting neural repair and circuit reformation to reverse persistent motor deficits after severe brain injury.
Regulatory and Commercial Outlook
Dr. Shuning Zhang, Senior Vice President of Clinical Affairs at Hopstem, commented: "Building on our previous FDA Fast Track designation, this RMAT recognition validates hNPC01's pioneering design and transformative clinical value as the world's first forebrain neural cell therapy candidate for chronic motor dysfunction caused by stroke or traumatic brain injury (search)."
The ischemic stroke program has now received multiple U.S. FDA regulatory recognitions, including Fast Track designation and RMAT designation, and has received FDA approval to enter a Phase 2/3 adaptive pivotal clinical trial with a bridging study. Hopstem continues advancing its global clinical development strategy for hNPC01 across ischemic stroke, hemorrhagic stroke (search), and traumatic brain injury (search), with plans to leverage global regulatory incentives and maintain close collaboration with clinical experts, industry stakeholders, and regulatory agencies worldwide.